Guardian Pharmacy Services (NYSE:GRDN) Trading Down 3.6% – Should You Sell?

Guardian Pharmacy Services, Inc. (NYSE:GRDN) shares fell 3.6% during mid-day trading on Tuesday . The stock traded as low as $22.76 and last traded at $22.80. 17,273 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 187,614 shares. The stock had previously closed at $23.65.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Stephens began coverage on shares of Guardian Pharmacy Services in a report on Tuesday, October 22nd. They set an “overweight” rating and a $21.00 price target on the stock. Truist Financial raised their target price on Guardian Pharmacy Services from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Finally, Raymond James assumed coverage on Guardian Pharmacy Services in a report on Monday, October 21st. They issued an “outperform” rating and a $21.00 price target for the company.

Guardian Pharmacy Services Price Performance

The company has a 50 day moving average of $21.32.

Guardian Pharmacy Services (NYSE:GRDN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($2.00) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($2.19). The company had revenue of $314.39 million for the quarter, compared to analysts’ expectations of $303.21 million. As a group, research analysts predict that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current fiscal year.

Insider Activity at Guardian Pharmacy Services

In other news, Director Steven D. Cosler acquired 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average price of $21.22 per share, for a total transaction of $148,540.00. Following the acquisition, the director now owns 17,713 shares of the company’s stock, valued at $375,869.86. This represents a 65.34 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Thomas J. Salentine, Jr. bought 35,714 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $499,996.00. Following the purchase, the director now owns 35,714 shares in the company, valued at $499,996. This represents a ∞ increase in their position. The disclosure for this purchase can be found here.

Institutional Investors Weigh In On Guardian Pharmacy Services

Several large investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. acquired a new position in Guardian Pharmacy Services during the 3rd quarter worth $8,575,000. Virtu Financial LLC purchased a new position in shares of Guardian Pharmacy Services in the 3rd quarter valued at about $279,000. Barclays PLC purchased a new position in shares of Guardian Pharmacy Services in the 3rd quarter valued at about $311,000. Wellington Management Group LLP acquired a new position in shares of Guardian Pharmacy Services during the third quarter worth about $8,400,000. Finally, Point72 DIFC Ltd acquired a new stake in Guardian Pharmacy Services in the third quarter valued at approximately $573,000.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.